PARP1 and hepatocellular carcinoma: Based on our findings, we propose that PCNA inhibition may sensitize HR-competent HCC to PARP inhibitors by destabilizing the PCNA/PARP1 axis, thereby exacerbating replication stress-induced genomic instability.